Bicycle Therapeutics PLC (BCYC) intrinsic value & 10-year financials
Bicycle Therapeutics PLC (BCYC) has no Graham intrinsic value right now because the formula needs positive earnings. Over the last 10 fiscal years revenue grew 56.1% a year to $72.6M, with an average return on invested capital of 126.2%.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $3.46
- Market cap
- $239.7M
- Revenue (FY2025)
- $72.6M
- Revenue growth (10-yr CAGR)
- 56.1%
- ROIC (10-yr avg)
- 126.2%
- Free cash flow (FY2025)
- -$252.0M
BCYC 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $72.6M | -$219.0M | -$3.16 | -$252.0M | -340.4% | 581.2% |
| FY2024 | $35.3M | -$169.0M | -$2.90 | -$166.0M | -595.0% | 207.2% |
| FY2023 | $27.0M | -$180.7M | -$5.08 | -$63.6M | -704.1% | 266.4% |
| FY2022 | $14.5M | -$112.7M | -$3.80 | -$105.1M | -806.6% | 296.4% |
| FY2021 | $11.7M | -$66.8M | -$2.67 | -$16.8M | -561.0% | -213.8% |
| FY2020 | $10.4M | -$51.0M | -$2.66 | -$19.0M | -500.1% | -50.0% |
| FY2019 | $13.8M | -$30.6M | -$2.77 | -$30.2M | -190.6% | -27.6% |
| FY2018 | $7.1M | -$21.8M | — | -$27.3M | -304.7% | 36.5% |
| FY2017 | $2.1M | -$16.3M | — | -$2.5M | -787.0% | 40.0% |
| FY2016 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
BICYCLE THERAPEUTICS PLC revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
BICYCLE THERAPEUTICS PLC has historically struggled to out-earn its cost of capital, averaging just -9.5% ROIC.
BICYCLE THERAPEUTICS PLC capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, BICYCLE THERAPEUTICS PLC is modeled at 15.0% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $-104.96 per share.